ethyl 1-formylpiperidine-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 1-formylpiperidine-4-carboxylate
• 化学式: C₉H₁₅NO₃
• 分子量: 185.223
• InChiKey: WEKYGPPUPKPAKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 1-formylpiperidine-4-carboxylate 、 sodium ethanolate 在 硫酸二甲酯 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以72%的产率得到ethyl 1-(diethoxymethyl)piperidine-4-carboxylate
  参考文献：
  名称：

  用N，N-二烷基甲酰胺缩醛合成5-（氨基亚甲基）咪唑-4-酮

  摘要：

  我们已经开发了一种简单的方法，用于通过原位制备的咪唑-4-酮与N，N-二烷基甲酰胺的缩醛缩合反应合成各种5-（氨基亚甲基）咪唑-4-酮。

  DOI：

  10.1007/s10593-020-02779-1
• 作为产物：
  描述：

  哌啶-4-甲酸乙酯 、 N,N-二甲基甲酰胺 在 叔丁基二甲硅基三氟甲磺酸酯 作用下， 反应 24.0h， 以88%的产率得到ethyl 1-formylpiperidine-4-carboxylate
  参考文献：
  名称：

  TBSOTf-promoted versatile N-formylation using DMF at room temperature

  摘要：

  Hydrazides and amines were N-formylated by DMF in the presence of tert-butyldimethylsilyl triflate (TBSOTf) at room temperature, in good to excellent yields. (C) 2019 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2019.04.010

文献信息

• Fluorene Compound and Pharmaceutical Use Thereof
  申请人：Motomura Takahisa

  公开号：US20100240634A1

  公开（公告）日：2010-09-23

  The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

  本发明提供了一种用于预防或治疗糖尿病、糖尿病并发症、胰岛素抵抗综合征、代谢综合征、高血糖、血脂异常、动脉粥样硬化、心力衰竭、心肌病、心肌缺血、脑缺血、脑卒中、肺动脉高压、高乳酸血症、线粒体疾病、线粒体脑病或癌症的药剂，即PDHK抑制剂等。一种由下式[I]表示的化合物或其药学上可接受的盐，或其溶剂：其中每个符号如规范中所定义。
• Carbazole derivatives and their use as neuropeptide y5 receptor ligands
  申请人：——

  公开号：US20040067999A1

  公开（公告）日：2004-04-08

  Compounds of formula (I): are described wherein R 1 -R 6 and m are as defined within. Processes for their preparation and their use as NPY 5 inhibitors is described.

  描述了化学式（I）的化合物，其中R1-R6和m的定义如所述。描述了它们的制备过程以及它们作为NPY 5抑制剂的用途。
• O-substituted hydroxyaryl derivatives
  申请人：Muto Susumu

  公开号：US20060094718A1

  公开（公告）日：2006-05-04

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C 1 to C 6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物具有抑制NF-κB激活活性，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物作为活性成分，其中X表示主链中原子数为2至5的连接基（该连接基可以被取代），A表示可以被取代的酰基（不包括未取代的乙酰基和未取代的丙烯酰基）或者可以被取代的C1到C6烷基，或者A可以与连接基X结合形成可以被取代的环状结构，E表示可以被取代的芳基或者可以被取代的杂环基，环Z表示可以具有一个或多个取代基的芳基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）或者可以具有一个或多个取代基的杂环基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）。
• FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：JAPAN TOBACCO INC.

  公开号：US20130274240A1

  公开（公告）日：2013-10-17

  The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

  本发明提供了一种用于预防或治疗糖尿病、糖尿病并发症、胰岛素抵抗综合征、代谢综合征、高血糖、血脂异常、动脉粥样硬化、心力衰竭、心肌病、心肌缺血、脑缺血、脑卒中、肺动脉高压、高乳酸血症、线粒体病、线粒体脑病或癌症的药剂，即PDHK抑制剂等。其中，化合物由以下式[I]表示，或其药学上可接受的盐或其溶剂：其中，每个符号如规范中所定义。
• Renininhibierende Aminosäurederivate
  申请人：MERCK PATENT GmbH

  公开号：EP0337334A2

  公开（公告）日：1989-10-18

  Neue Aminosäurederivate der Formel I R¹-CpH2p-(NH)y-CO-NH-CHR²-CO-Z-CmH2m-CO-­NH-CHR³-CR⁴-(CHR⁵)n-CO-E-Q-Y      I worin R¹ bis R⁵, p, y, Z, m, n, E, Q und Y die in Patent­anspruch 1 angegebenen Bedeutungen haben, sowie ihre Salze hemmen die Aktivität des menschlichen Plasmarenins.

  式 I 的新氨基酸衍生物 R¹-CpH2p-(NH)y-CO-NH-CHR²-CO-Z-CmH2m-CO-NH-CHR³-CR⁴-(CHR⁵)n-CO-E-Q-Y I 其中 R¹ 至 R⁵、p、y、Z、m、n、E、Q 和 Y 具有权利要求 1 中给出的含义、 及其盐类可抑制人血浆肾素的活性。